Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CDK4 | P11802 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCND1 | P24385 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10648882 | 0.89 | ALDH1A1 (0.67) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL6000358 | 0.88 | ALDH1A1 (0.65) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL9428004 | 0.88 | ALDH1A1 (0.65) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL1299790 | 0.87 | HPGD (0.59) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL28788684 | 0.85 | CCNB2 (0.52) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL6914412 | 0.84 | ALDH1A1 (1.00) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL433401 | 0.83 | CCNB2 (0.72) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL29537861 | 0.83 | CCNB2 (0.72) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL3744999 | 0.82 | ALDH1A1 (0.49) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 | |
| SCHEMBL8372730 | 0.82 | ALDH1A1 (0.87) | ALDH1A1HPGDHTTSMN1; SMN2PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-2678440-A2 | YEAST STRAIN FOR THE PRODUCTION OF PROTEINS WITH MODIFIED O-GLYCOSYLATION | Merck Sharp & Dohme Corp. (US) | 2014-01-01 | — | — | EP | disclosed |
| WO-2012115903-A2 | YEAST STRAIN FOR THE PRODUCTION OF PROTEINS WITH MODIFIED O-GLYCOSYLATION | MERCK SHARP & DOHME CORP. (US) | 2012-08-30 | — | — | WO | disclosed |
| CN-101111483-B | IGF-1R inhibitors | KYOWA HAKKO KIRIN CO.,LTD. (JP) | 2011-12-14 | — | — | CN | disclosed |
| EP-2304029-A1 | SURFACE DISPLAY OF WHOLE ANTIBODIES IN EUKARYOTES | Merck & Co., Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010005863-A1 | SURFACE DISPLAY OF WHOLE ANTIBODIES IN EUKARYOTES | MERCK & CO., INC. (US) | 2010-01-14 | — | — | WO | disclosed |
| US-7605272-B2 | IGF-1R inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090054508-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| CN-101111483-A | IGF-1R inhibitors | KYOWA HAKKO KOGYO KK (JP) | 2008-01-23 | — | — | CN | disclosed |
| EP-1847532-A1 | IGF-1R INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-0733033-B1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LTD (GB) | 1999-12-22 | — | — | EP | disclosed |
| US-5811459-A | PAIN RELIEVERS | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | disclosed |
| EP-0733033-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
| US-4760064-A | Cardiotonic agent | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-07-26 | — | — | US | disclosed |
| EP-0187322-A1 | Carbostyril compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054508-A1 | IGF-1R INHIBITOR | IGF1R, IGFBP5, IGFBP1 | ALDH1A1 1250/4885HPGD 4033/4885HTT 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.